BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20232326)

  • 1. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
    Ahmad S
    Chem Biodivers; 2010 Mar; 7(3):543-66. PubMed ID: 20232326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
    Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
    Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
    Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J; Novakova O; Farrell N; Brabec V
    Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
    Chaney SG; Campbell SL; Bassett E; Wu Y
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
    Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
    Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular processing of platinum anticancer drugs.
    Wang D; Lippard SJ
    Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleotide excision repair from site-specifically platinum-modified nucleosomes.
    Wang D; Hara R; Singh G; Sancar A; Lippard SJ
    Biochemistry; 2003 Jun; 42(22):6747-53. PubMed ID: 12779329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein interactions with platinum-DNA adducts: from structure to function.
    Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
    J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts.
    Bassett E; King NM; Bryant MF; Hector S; Pendyala L; Chaney SG; Cordeiro-Stone M
    Cancer Res; 2004 Sep; 64(18):6469-75. PubMed ID: 15374956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
    Lippert B
    Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding.
    Kasparkova J; Vrana O; Farrell N; Brabec V
    J Inorg Biochem; 2004 Oct; 98(10):1560-9. PubMed ID: 15458817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
    Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin: mechanism of action and antineoplastic activity.
    Raymond E; Faivre S; Woynarowski JM; Chaney SG
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT; Vaisman A; Chaney SG; Sancar A
    Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition and repair of DNA-cisplatin adducts.
    Woźniak K; Błasiak J
    Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.